S
Shilpee Dutt
Researcher at Homi Bhabha National Institute
Publications - 54
Citations - 2506
Shilpee Dutt is an academic researcher from Homi Bhabha National Institute. The author has contributed to research in topics: Medicine & Cancer research. The author has an hindex of 19, co-authored 46 publications receiving 2204 citations. Previous affiliations of Shilpee Dutt include University of Manchester & University of Zurich.
Papers
More filters
Journal ArticleDOI
Microscopic activity in ulcerative colitis: what does it mean?
TL;DR: The presence of a chronic inflammatory cell infiltrate or crypt architectural irregularities bore no relation to the frequency of colitis relapse and relapse rates were higher in the presence of crypt abscesses, mucin depletion, and breaches in the surface epithelium.
Journal ArticleDOI
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells
Shilpee Dutt,Anupama Narla,Anupama Narla,Anupama Narla,Katherine Lin,Ann Mullally,Nirmalee Abayasekara,Christine Megerdichian,Frederick H. Wilson,Treeve Currie,Arati Khanna-Gupta,Nancy Berliner,Jeffery L. Kutok,Benjamin L. Ebert,Benjamin L. Ebert +14 more
TL;DR: The findings indicate that the erythroid lineage has a low threshold for the induction of p53, providing a basis for the failure of erythropoiesis in the 5q-syndrome, DBA, and perhaps other bone marrow failure syndromes.
Journal ArticleDOI
The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation
Uttiya Basu,Jayanta Chaudhuri,Jayanta Chaudhuri,Craig Alpert,Shilpee Dutt,Sheila Ranganath,Gang Li,Jason P. Schrum,John P. Manis,Frederick W. Alt +9 more
TL;DR: AID from non-lymphoid cells can be functionally phosphorylated by recombinant PKA to allow interaction with RPA and promote deamination of transcribed dsDNA substrates, and PKA has a critical role in post-translational regulation of AID activity in B cells.
Journal ArticleDOI
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
TL;DR: In this paper, the authors compared sulphasalazine, low dose mesalazine and high dose mesaline in the treatment of mild to moderate relapse of ulcerative colitis.
Journal ArticleDOI
Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis
TL;DR: Delayed-release mesalazine is an effective treatment for maintaining ulcerative colitis remission and is associated with fewer side effects than equivalent doses of enteric-coated sulfasalazine.